News

Jan 18, 2022 Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Dec 22, 2021 Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

Dec 06, 2021 Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

Nov 24, 2021 Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 "A Town Hall Q&A Event With Atossa Therapeutics Management Team"

Nov 15, 2021 Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Oct 21, 2021 Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month

Sep 30, 2021 Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

Sep 07, 2021 Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Sep 02, 2021 Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

Aug 13, 2021 Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

<< < > >>